IPC분류정보
| 국가/구분 |
United States(US) Patent
등록
|
| 국제특허분류(IPC7판) |
|
| 출원번호 |
US-0081422
(2011-04-06)
|
| 등록번호 |
US-8562973
(2013-10-22)
|
|
발명자
/ 주소 |
- Edinger, James W.
- Fischkoff, Steven Alan
- Francki, Aleksandar
- Jankovic, Vladimir
- Liang, Bitao
- Martin, Philippe
- Ray, Cynthia
- Zhang, Xiaokui
|
| 출원인 / 주소 |
- Anthrogenesis Corporation
|
| 대리인 / 주소 |
|
| 인용정보 |
피인용 횟수 :
5 인용 특허 :
179 |
초록
▼
Methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder using placental cells are described. Also describe are kits comprising placental stem cells or a composition thereof that can be used in methods of treating sarcoidosis or a sarcoidosis-related disease or
Methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder using placental cells are described. Also describe are kits comprising placental stem cells or a composition thereof that can be used in methods of treating sarcoidosis or a sarcoidosis-related disease or disorder.
대표청구항
▼
1. A method of treating an individual having sarcoidosis comprising administering to the individual a therapeutically effective amount of placental stem cells, wherein the therapeutically effective amount is an amount sufficient to cause a detectable improvement in one or more symptoms of said sarco
1. A method of treating an individual having sarcoidosis comprising administering to the individual a therapeutically effective amount of placental stem cells, wherein the therapeutically effective amount is an amount sufficient to cause a detectable improvement in one or more symptoms of said sarcoidosis and wherein said sarcoidosis is systemic sarcoidosis, cutaneous sarcoidosis, Löfgren's syndrome, neurosarcoidosis, cardiac sarcoidosis, or ocular sarcoidosis. 2. The method of claim 1, wherein said placental stem cells are CD10+, CD3431 , CD105+, CD200+placental stem cells. 3. The method of claim 2, wherein said placental stem cells are additionally CD45−or CD90+. 4. The method of claim 2, wherein said placental stem cells are additionally one or more of CD38−, CD45−, CD80−, CD86−, CD133−, HLA-DR,DP,DQ−, SSEA3−, SSEA4−, CD29+, CD44+, CD73+, CD90+, HLA-A,B,C+, PDL1+, ABC-p+,or OCT-4+. 5. The method of claim 2, wherein said placental stem cells are additionally one or more of CD29+, CD38+, CD44+, CD54+, SH3+or SH4+. 6. The method of claim 2, wherein said placental stem cells are additionally CD44+. 7. The method of claim 1, wherein said placental stem cells express CD200 and do not express HLA-G, or express CD73, CD 105, and CD200, or express CD200 and OCT-4, or express CD73 and CD 105 and do not express HLA-G, or express CD73 and CD105 and facilitate the formation of one or more embryoid-like bodies in a population of placental cells comprising said stem cell when said population is cultured under conditions that allow for the formation of an embryoid-like body, or express OCT-4 and facilitate the formation of one or more embryoid-like bodies in a population of placental cells comprising said stem cell when said population is cultured under conditions that allow for the formation of an embryoid-like body. 8. The method of claim 1, wherein said sarcoidosis is systemic sarcoidosis. 9. The method of claim 8, wherein said symptom is one or more of formation of granulomas, fatigue, weight loss, fever, aches, pains, arthritis, dry eyes, swelling of the knees, blurry vision, shortness of breath, cough and skin lesions. 10. The method of claim 1, wherein said sarcoidosis is cutaneous sarcoidosis. 11. The method of claim 10, wherein the cutaneous sarcoidosis comprises annular sarcoidosis, erythrodermic sarcoidosis, ichthyosiform sarcoidosis, hypopigmented sarcoidosis, morpheaform sarcoidosis, mucosal sarcoidosis, papular sarcoid, scar sarcoid, subcutaneous sarcoidosis or ulcerative sarcoidosis. 12. The method of claim 11, wherein said symptom is a skin lesion. 13. The method of claim 12, wherein the skin lesion is one or more of erythema nodosum, nummular eczema, erythema multiforme, calcinosis cutis and pruritus, lupus pernio, skin plaques, maculopapular eruptions, nodular lesions deeper in the skin or infiltration of old scars. 14. The method of claim 1, wherein said sarcoidosis is Löfgren's syndrome. 15. The method of claim 14, wherein said symptom is one or more of erythema nodosum, bilateral hilar denopathy, arthritis, arthralgias or fever. 16. The method of claim 1, wherein said sarcoidosis is neurosarcoidosis. 17. The method of claim 16, wherein said symptom is one or more of formation of granulomas in the nervous system, headache, confusion, malaise or facial paralysis. 18. The method of claim 1, wherein said sarcoidosis is cardiac sarcoidosis. 19. The method of claim 18, wherein said symptom is one or more of chest pain, palpitations, congestive heart failure, pericarditis or papillary muscle dysfunction, shortness of breath, ankle swelling, irregular heart beat or sudden death. 20. The method of claim 1, wherein said sarcoidosis is ocular sarcoidosis. 21. The method of claim 20, wherein said symptom is one or more of red or watery eyes, granulomatous uvetis, iris nodules, retinochoroiditis, conjunctivitis, lacrimal gland involvement or proptosis. 22. The method of claim 1, comprising administering a second therapeutic agent to said individual. 23. The method of claim 22, wherein said second therapeutic agent is an anti-inflammatory agent, a steroid, an immunosuppressant compound, or an antibiotic.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.